Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jdermsci.2020.09.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Managing Hidradenitis Suppurativa with Biologics and Small Molecule Inhibitors.
Dermatol Clin
April 2025
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, PCAM 7 South, Room 724, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. Electronic address:
"Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a significant quality-of-life impact. In addition to the 2 drugs approved by the Food and Drug Administration for HS, adalimumab and secukinumab, several other biologic and small molecule inhibitors are used off-label or are in clinical trials. A systematic and evidence-based approach using these and other therapies-considering patient comorbidities, response to therapy, dose adjustment, and frequent troubleshooting-is required.
View Article and Find Full Text PDFRegulating ferroptosis by roflumilast attenuates cisplatin-induced kidney injury.
Int Immunopharmacol
April 2025
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, 35516 Mansoura, Egypt. Electronic address:
Acute kidney injury (AKI) represents a concerning health challenge that alters renal structure and function. Ferroptosis has been identified as a cell death mechanism involved in AKI. Cisplatin is a widely used antineoplastic agent, but AKI is a serious limitation to its clinical use.
View Article and Find Full Text PDFHow close are we to a cAMP- and cGMP-theory-based pharmacological therapy for fragile X syndrome?
Cell Rep Med
February 2025
Syneos Health Sophia, 06410 Biot, France.
Recent advances in targeting cAMP and cGMP pathways offer hope for treating fragile X syndrome, a leading cause of inherited intellectual disability. PDE4 and PDE2 inhibitors have shown promise in animal models, improving memory, social behavior, and cognitive function. Clinical trials are underway, raising optimism for future therapies.
View Article and Find Full Text PDF5-hydroxymethylcytosine features of portal venous blood predict metachronous liver metastases of colorectal cancer and reveal phosphodiesterase 4 as a therapeutic target.
Clin Transl Med
February 2025
Department of Pharmacy, Peking University Third Hospital, Beijing, China.
Metachronous liver metastases (MLM) are characterised by high incidence and high mortality in clinical colorectal cancer treatment. Currently traditional clinical methods cannot effectively predict and prevent the occurrence of metachronous liver metastasis in colorectal cancer. Based on 5hmC-Seal analysis of blood and tissue samples, this study found that portal venous blood was more relevant to tumour gDNA than peripheral blood.
View Article and Find Full Text PDFPDE4B Modulates Phosphorylation of p65 (Ser468) via cAMP/PKA in Acute Lung Injury.
Lung
February 2025
Department of Pharmacology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310058, Zhejiang, China.
Aim: The important role of phosphodiesterase 4B (PDE4B) inhibition on lipopolysaccharide (LPS)-induced ALI has been reported. However, the corresponding mechanisms remain unclear. In the present study, the relationship between PDE4B and phosphorylation of p65 (Ser468) in LPS-induced injury by in vivo and in vitro models was investigated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!